Published in final edited form as:

Tetrahedron Lett. 2010 December 8; 51(49): 6426–6428. doi:10.1016/j.tetlet.2010.09.139.

Chemical synthesis of deuterium-labeled and unlabeled very long chain polyunsaturated fatty acids

Ghulam M. Maharvi^a, Albert O. Edwards^{b,*}, and Abdul H. Fauq^{a,*}

^aChemical Synthesis Core Facility, Mayo Clinic Jacksonville, FL 32246, USA

^bInstitute for Molecular Biology, University of Oregon, Eugene, OR, 97403, USA

Abstract

First syntheses of a deuterium-labeled very long C34-containing polyunsaturated fatty acid, C34:5n5.d₂, and three other unlabeled very long chain C30–32-containing polyunsaturated fatty acids are reported here. These syntheses were achieved by coupling chemically modified C22- and C20-containing polyunsaturated fatty acids with carbanions derived from arylalkyl sulfones, followed by sodium amalgam-mediated desulfonylation.

Very long chain polyunsaturated fatty acids (VLC-PUFAs) are arbitrarily defined as fatty acids that have 24 or more carbon atoms in their molecules with cis-double bonds interrupted by methylene units. These fatty acids found in most living organisms from humans to autotrophic and heterotrophic lower organisms can be grouped into two molecular families: omega-6 (or n-6) and omega-3 (or n-3) families, where the number 6 or 3 represents the position of the first double bond proximal to the terminal methyl group.

Dietary intervention studies suggest that omega-3 PUFAs such as eicosapentaenoic acid (EPA; 20:5D5,8,11,14,17) and docosahexaenoic acid (DHA; 22:6D4,7,10,13,16,19) confer health benefits to humans.^{1–3} PUFAs are also widely distributed in higher plants.⁴ Humans, like other animals, can synthesize PUFAs from the essential α -linolenic acid⁵ and the PUFA are distributed throughout the body. However, the distribution of VLC-PUFAs appears to be more limited, being found in retina, brain,¹ testis, and spermatozoa.⁶ The VLC-PUFAs with 3–9 double bonds are not only susceptible to oxidative damage but are also difficult to separate from mammalian tissues for characterization.⁷ Therefore, not much is known about the metabolism and function of VLC-PUFAs.

© Published by Elsevier Ltd.

* fauq.abdul@mayo.edu . * edwardsa@uoregon.edu .

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Data The Supplementary Data section, consisting of the chemical synthesis procedures and spectral data of the final VLC-PUFAs and their synthetic intermediates reported in this article, can be found in the online version, at....

Animal models of an early on set form for macular degeneration (autosomal dominant Stargardt-like macular dystrophy, STGD3) were used to show that this human disease arises due to a deficiency of VLC-PUFAs in the retina.⁸ Mutation of the gene encoding elongation of very long chain fatty acid 4 (*ELOVL4*) lead to STGD3.⁹ *ELOVL4* has been shown to elongate of long fatty acids to form VLC-PUFAs.¹⁰ Thus, the VLC-PUFAs present in retina have recently seen a renewed interest because of their important role in vision.

Even though aspects of metabolic engineering of some specific VLC-PUFA are reported¹⁶, to the best of our knowledge, their chemical laboratory synthesis has not been described. In order to evaluate the retinal role of VLC-PUFA in the vision process in our ongoing epidemiological studies, we have synthesized a variety of VLC-PUFAs with carbon chains varying between C-30 to C-34 and with three, four, and five *cis*-oriented C-C double bonds (Figure 1). Additionally, we prepared a dideuterated version of a C-34 omega-3 VLC-PUFA, 34:5n3.d₂ to be used as a probe in our studies. For convenience, all VLC-PUFA materials were synthesized using C-20 and C-22-containing all-*cis* fatty acids available commercially (Nu-Chek Prep, Inc). Care was taken to select reagents that are not expected to invert geometrical integrity of the C-C double bonds. Additionally, all reactions were carried under argon in flasks covered with aluminium foil to prevent oxidation.

Our first priority was to prepare a deuterium-labeled omega-3 fatty acid 34:5n3 with a difference of at least 2 mass units. Cost considerations suggested incorporating two deuterium atoms at a location near the middle of the saturated part of the long carbon chain that was less likely to be prone to deuterium exchange under our bioassay conditions. To this end, 12-bromododecanol (**1**) (Scheme 1) was protected with a robust *t*-butyldiphenylsilyl (TBDPS) group to give the bromosilyl ether **2**. Next, the bromide function of **2** was displaced with a sulfinate anion in *N,N*-dimethylformamide (DMF) to generate the sulfone fragment **3** in 94% yield over two steps.¹¹

In a separate pot, omega-3-all-*cis*-docosapentaenoic acid **4** was reduced either directly with lithium aluminium deuteride in tetrahydrofuran solvent, or via cyanuric fluoride-mediated acyl fluoride formation¹² followed by sodium borodeuteride reduction,¹³ to give an alcohol that was immediately converted to the desired deuterated *p*-toluenesulfonate ester **5** in 71% yield over two steps.

For coupling the sulfone fragment **3** with the fatty acid tosylate fragment **5**, the sulfone **3** was deprotonated to a lithocarbocation with *n*-butyllithium in tetrahydrofuran at -78 °C and reacted with the tosylate **5** to furnish the deuterated sulfone **6** in 95% yield. The TBDPS group was removed with tetra-*n*-butylammonium fluoride (94%) and the resulting alcohol was carefully oxidized with the Jones reagent¹⁴ in acetone (83%) to give the polyunsaturated fatty acid **7**. Finally, the phenylsulfone moiety of **7** was reductively removed by treating it with sodium amalgam in methanol under phosphate buffer conditions¹⁵ furnishing the VLC-PUFA 34:5n3 **8** after purification to homogeneity by flash silica gel chromatography. The overall yield of this 8-step convergent synthetic sequence leading to the VLC-PUFA **8** was 38%.

For some of our ongoing projects, two unlabeled omega-6 VLC-PUFAs, namely, 30:3n6 and 32:4n6 (Scheme 2) were also synthesized using the methodology described above. These syntheses employed omega-6-all-*cis*-octadecatrienoic acid (18:3n6, **9a**) and omega-6-all-*cis*-icosatetraenoic acid (20:4n6, **9b**) as the starting polyunsaturated fatty acid starting materials. Starting from the sulfone **3**, the entire synthetic sequence proceeded without incident and furnished the final VLC-PUFAs C30:3n6 (**13a**) and C32:4n6 (**13b**) with overall yields similar to **8**.

As a negative control, we also synthesized C32:4+1(12)n6, an unusual VLC-PUFA with a *cis*-C-C double bond at the C-12 position, separated from the nearest C-C double bond by three methylene groups rather than the usual one. As graphically represented in Scheme 3, the omega-6-all-*cis*-icostetraenoic acid (20:4n6, **9b**, was reduced with lithium aluminium hydride in THF to the primary alcohol **14**, that was then partially oxidized to the aldehyde **15**. In a Wittig reaction, the aldehyde **15** was coupled with the phosphorane derived from phosphonate **17**, itself derived from the protected bromoalcohol **16**, to give a silyl-protected alcohol **18**, from which the alcohol was recovered by desilylation and oxidized under Jones oxidation to the VLC-PUFA 32:4+1(12)n6 **19**. In this case, the overall synthetic sequence starting from **9b** and 12-bromododecanol (**2**) proceeded in 8.1% combined yield.

The VLC-PUFAs as well as all the synthetic intermediates were purified by flash silica gel chromatography and their structures were confirmed by ¹H-NMR and ESI/APCI-mass spectroscopy. Furthermore, in view of their expected rapid oxidation, all synthesized VLC-PUFAs were stored away from light at -80 °C under argon. They were found to be stable at least for several weeks as judged by their unchanged spectral properties.

In conclusion, in order to elucidate their biological role in the vision process and related areas, the first practical and general chemical synthetic method for several very long chain polyunsaturated fatty acids is described. The overall 8-step synthesis methodology reported herein proceeded in reasonable yield and can be employed for most VLC-PUFAs required for activity and role elucidation in any biological system.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The research was supported by the National Institutes of Health (EY014467), Bethesda, MD and the Foundation Fighting Blindness, Owing Mills, MD.

References and notes

1. Bang HO, Dyerberg J, Hjoorne N. Acta Med. Scand 1976;200:69–73. [PubMed: 961471] For a thematic review, see: Agbaga M-P, Mandal MNA, Anderson RE. J. Lipid Res 2010;51:1624–1642. [PubMed: 20299492] .
2. Kromann N, Green A. Acta Med. Scand 1980;208:401–406. [PubMed: 7457208]
3. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Lancet 1989;2:757–761. [PubMed: 2571009]
4. (a) Rezanka T. Prog. Lipid Res 1989;28:147–187. [PubMed: 2694175] (b) Poulos A. Lipids 1995;30:1–14. [PubMed: 7760683]
5. Riediger ND, Othman RA, Suh M, Moghadasian MH. J. Am. Diet Assoc 2009;109:668–679. [PubMed: 19328262]
6. Aveldano MI, Robinson BS, Johnson DW, Poulos A. J. Biol. Chem 1993;268:11663–11669. [PubMed: 8505297]
7. Rezanka T, Sigler K. Prog. Lipid Res 2009;48:206–238. [PubMed: 19336244]
8. McMahon A, Butovich IA, Mata NL, Klein M, Ritter R 3rd, Richardson J, Birch DG, Edwards AO, Kedziarski W. Mol. Vis 2007;13:258–272. [PubMed: 17356513]
9. Edwards AO, Donoso LA, Ritter R 3rd. Invest. Ophthalmol. Vis. Sci 2001;42:2652–2663. [PubMed: 11581213]
10. Agbaga MP, Brush RS, Mandal MNA, Henry K, Elliott MH, Anderson RE. Proc. Natl. Acad. Sci. USA 2008;105:12843–12848. [PubMed: 18728184]

11. Schank, K. The Chemistry of Sulfones and Sulfoxides. Patai, S.; Rappoport, Z.; Stirling, CJM., editors. Wiley; New York: 1988. Chapter 7
12. Olah GA, Nojima M, Kerekes I. Synthesis 1973:487–488.
13. Wheeler, OH. Reduction. In: Patai, S., editor. The Chemistry of Acyl Halides. John Wiley Sons; NewYork: 1972. p. 231-251.
14. Bowden K, Heilbron IM, Jones ERH, Weedon BCL. J. Chem. Soc 1946:39–45.
15. (a) Carr RVC, Williams RV, Paquette LA. J. Org. Chem 1983;48:4976–4986. (b) Kinney WA, Crouse GD, Paquette LA. J. Org. Chem 1983;48:4986–5000.
16. For a recent review, see: Venegas-Calderón M, Sayanova O, Napier JA. Prog. Lipid Res 2010;49:108–119. [PubMed: 19857520] .

Figure 1.
Structures of synthesized VLC-PUFAs

Scheme 1.
Synthesis of 34:5n3.d2

Scheme 2. Synthesis of 32:4n6 and 30:3 n6
 (Yields reported in series **a**, X = C₆H₅; in series **b**, X = CH)

Scheme 3.
Synthesis of 32:4+1(12)n6